P
Philip L. McCarthy
Researcher at Roswell Park Cancer Institute
Publications - 54
Citations - 9027
Philip L. McCarthy is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Transplantation & Multiple myeloma. The author has an hindex of 28, co-authored 54 publications receiving 7802 citations. Previous affiliations of Philip L. McCarthy include Howard Hughes Medical Institute & Medical College of Wisconsin.
Papers
More filters
Journal ArticleDOI
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar,Bruno Paiva,Kenneth C. Anderson,Brian G.M. Durie,Ola Landgren,Philippe Moreau,Nikhil C. Munshi,Sagar Lonial,Joan Bladé,Maria-Victoria Mateos,Meletios A. Dimopoulos,Efstathios Kastritis,Mario Boccadoro,Mario Boccadoro,Robert Z. Orlowski,Hartmut Goldschmidt,Andrew Spencer,Jian Hou,Wee Joo Chng,Saad Z. Usmani,Elena Zamagni,Kazuyuki Shimizu,Sundar Jagannath,Hans Erik Johnsen,Evangelos Terpos,Anthony Reiman,Robert A. Kyle,Pieter Sonneveld,Paul G. Richardson,Philip L. McCarthy,Heinz Ludwig,Wenming Chen,Michele Cavo,Jean Luc Harousseau,Suzanne Lentzsch,Jens Hillengass,Antonio Palumbo,Alberto Orfao,S. Vincent Rajkumar,Jesús F. San Miguel,Hervé Avet-Loiseau +40 more
TL;DR: Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials.
Journal ArticleDOI
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L. McCarthy,Kouros Owzar,Craig C. Hofmeister,David D. Hurd,Hani Hassoun,Paul G. Richardson,Sergio Giralt,Edward A. Stadtmauer,Daniel J. Weisdorf,Ravi Vij,Jan S. Moreb,Natalie S. Callander,Koen van Besien,Teresa Gentile,Luis Isola,Richard T. Maziarz,Don A. Gabriel,Asad Bashey,Heather Landau,Thomas G. Martin,Muzaffar H. Qazilbash,Denise Levitan,Brian McClune,Robert L. Schlossman,Vera Hars,John Postiglione,Chen Jiang,Elizabeth Bennett,Susan Barry,Linda Bressler,Michael Kelly,Michele Seiler,Cara A. Rosenbaum,Parameswaran Hari,Marcelo C. Pasquini,Mary M. Horowitz,Thomas C. Shea,Steven M. Devine,Kenneth C. Anderson,Charles A. Linker +39 more
TL;DR: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
Journal ArticleDOI
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients
Hillard M. Lazarus,Omer N. Koc,Steven M. Devine,Peter T. Curtin,Richard T. Maziarz,H. Kent Holland,Elizabeth J. Shpall,Philip L. McCarthy,Kerry Atkinson,Brenda W. Cooper,Stanton L. Gerson,Mary J. Laughlin,Fausto R. Loberiza,Annemarie Moseley,Andrea Bacigalupo +14 more
TL;DR: Cotransplantation of HLA-identical sibling culture-expanded MSCs with an HLA and hematopoietic HSC transplant is feasible and seems to be safe, without immediate infusional or late MSC-associated toxicities.
Journal ArticleDOI
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo,Sara Bringhen,Maria-Victoria Mateos,Alessandra Larocca,Thierry Facon,Shaji Kumar,Massimo Offidani,Philip L. McCarthy,Andrea Evangelista,Sagar Lonial,Sonja Zweegman,Pellegrino Musto,Evangelos Terpos,Andrew Belch,Roman Hájek,Heinz Ludwig,A. Keith Stewart,Philippe Moreau,Kenneth C. Anderson,Hermann Einsele,Brian G.M. Durie,Meletios A. Dimopoulos,Ola Landgren,Jesús F. San Miguel,Paul G. Richardson,Pieter Sonneveld,S. Vincent Rajkumar +26 more
TL;DR: The frailty score predicts mortality and the risk of toxicity in elderly myeloma patients and is proposed for the measurement of frailty in designing future clinical trials.
Journal ArticleDOI
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Madan Jagasia,Mukta Arora,Mary E.D. Flowers,Nelson J. Chao,Philip L. McCarthy,Corey Cutler,Alvaro Urbano-Ispizua,Steven Z. Pavletic,Michael Haagenson,Mei-Jie Zhang,Joseph H. Antin,Brian J. Bolwell,Christopher Bredeson,Jean-Yves Cahn,Mitchell S. Cairo,Robert Peter Gale,Vikas Gupta,Stephanie J. Lee,Mark R. Litzow,Daniel J. Weisdorf,Mary M. Horowitz,Theresa Hahn +21 more
TL;DR: Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.